Format

Send to

Choose Destination
J Surg Oncol. 2018 Apr;117(5):840-844. doi: 10.1002/jso.25001. Epub 2018 Mar 12.

Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?

Author information

1
Oncology Surgical Department, Sociedade Pernambucana de Combate ao Câncer-Hospital do Cancer de Pernambuco (SPCC-HCP), Recife, Brazil.
2
Translational Research Laboratory Prof. C. A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
3
Surgical Department, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
4
Anatomic Pathology Department, A.C. Camargo Cancer Center, São Paulo, Brazil.

Abstract

BACKGROUND AND OBJECTIVES:

OX40, a membrane-bound molecule of the tumor-necrosis-factor-receptor superfamily, is a critical costimulatory receptor during the immune response, especially to T cells, but studies described their presence of OX-40 on neutrophils and monocytes, suggesting a potential role in the activation of immune response. Our aim was to characterize costimulatory receptors OX40 expression on circulating leukocytes in gastric cancer to identify novel targets for immunotherapy.

METHODS:

Peripheral blood mononuclear cells were isolated from 24 gastric cancer patients and 34 healthy controls and the expression of costimulatory (OX40) receptors were analyzed on T cells, neutrophil and monocyte using monoclonal antibodies by flow cytometry.

RESULTS:

We found that the higher levels of OX40 + T cells, monocytes/OX40+ and neutrophils/OX40+ from gastric cancer patients when compared to controls (P < 0.0001), and also higher levels of OX40+ T cells when compared to stages III and IV (P  = 0.02). Percentage levels of total T cells were similar between patients and controls.

CONCLUSIONS:

OX40 as a therapeutic agent has been investigated in many preclinical tumor models. Our findings suggest that of levels of costimulatory in T cells in GC will direct future studies on the role that costimulatory receptors play in the failure of T cell-mediated immunity.

KEYWORDS:

immunotherapy; neoplasm; receptor OX40 (CD134); stomach

PMID:
29529339
DOI:
10.1002/jso.25001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center